News

Spotlight On… Medidata buys out Intelemage; Pharm-Olam appoints new exec; and more…

large can lights shining down

        The New York, cloud-based clinical research solutions team Medidata ($MDSO) has acquired the Cincinnati, OH-headquartered Intelemage as it looks to expand its medical imaging services. Medidata will integrate Intelemages technology into its Clinical Cloud program, offering customers what it calls "an end-to-end solution to capture, manage and analyze medical imaging data." Founded in 2007, Intelemage uses medical image file sharing in clinical trials as well as for hospitals, doctors, life science companies, research institutions and core labs. The company also provides tools for medical imaging data capture and workflow management. This follows a spate of deals for Medidata that includes tie-ups with Apples ($AAPL) ResearchKit and broadening its geographical reach with a recent collaboration in South Korea. Financial details of the Intelemage deal were not disclosed. Release

        > Houston, TX-based CRO Pharm-Olam International has appointed Tricia Bland to its management team as its new executive director of strategic projects. Release

        > The EMA has said it will review a number of medicines for which studies have been conducted at the Alkem Laboratories site in Taloja, India, where the company tests the bioequivalence of its generics. This follows a recent GCP inspection of the site that raised concerns regarding study data used to support the drug applications of some medicines in the EU. Release



Excerpt from URL:https://www.fiercebiotech.com/cro/spotlight-on%E2%80%A6-medidata-buys-out-intelemage-pharm-olam-appoints-new-exec-and-more%E2%80%A6



  ▲ Last article:   Welcome to the new and improved FierceBiotech ---Apr 10, 2016
  ▼ Next article:   InVentiv hopes to raise $500M with IPO ---Apr 6, 2016
                    More ……      

 



News FullText Search